Chinese Journal of Pharmacovigilance ›› 2021, Vol. 18 ›› Issue (4): 356-360.
DOI: 10.19803/j.1672-8629.2021.04.13

Previous Articles     Next Articles

443 Cases of Drug - Induced Adverse Reactions in Blood System

ZHU Dan, CAO Xue, SONG Yanqing, LI Yanjiao*   

  1. Department of Pharmacy, the First Hospital of Jilin University, Changchun Jilin 130021, China
  • Received:2019-11-29 Online:2021-04-15 Published:2021-04-23

Abstract: Objective To analyze the characteristics of adverse reactions in the blood system caused by drugs in a hospital so as to provide reference for drug safety and rational drug use in clinic. Methods Retrospective analysis was performed on the blood system adverse reactions reported by a hospital to the National Drug for ADR Monitoring, China from November 2014 to November 2019, involving gender, age, dosage forms, routes of administration, clinical manifestations, drug varieties, clinical outcomes, and off-label prescriptions. Results From November 2014 to November 2019, our hospital reported a total of 443 cases of drug-induced ADRs in the blood system, 313 (70.65%) of which were normal ADR, and130 (29.35%) were severe ADR. 258 (58.24%) of these cases involved males and 185 (41.76%) involved females. Sixty-one drugs of 10 categories were involved, with the largest proportion going to anti-tumor drug (51.92%). There were 39 cases of ADR related to off-label drugs. The clinical manifestations of ADR were mostly platelet/hemorrhage and coagulation disorder, and most of the ADR occurred within 0~3d (223 cases) of medication. In 402 of these cases (90.74%), ADR had no significant effect on the preexisting disease, but 31 of these cases (7.00%) refused to improve, and 10 cases (2.26%) lost contact. Conclusion ADR associated with the blood system are severe and hidden, so precautions should be taken. Medical staff should enhance the public awareness of adverse reactions so as to reduce and prevent the occurrence of ADR.

Key words: damage to the blood system, adverse drugs, reactions, retrospective analysis

CLC Number: